Gilead Sciences (GILD) stock had a bullish inflow of $29.86 million worth of trades on uptick and an outflow of $12.14 million in downticks on Monday. The total uptick to downtick ratio stood at 2.46. The net money flow into the stock was $17.72 million. The money flow data, which is calculated as the dollar value of composite uptick minus the downtick trades indicated bullish. The block trades had a total money flow of $17.95 million. $17.95 million of block trade during Uptick was observed, which shows continued buying by the smart money on every weakness. However, Gilead Sciences (GILD) stock traded down $0.15 , and reached $86.52, a drop of -0.17% over the previous day. On a weekly basis, the stock is -0.03%, over the previous weeks close.
Gilead Sciences Inc. has dropped 11.88% during the last 3-month period . Year-to-Date the stock performance stands at -13.19%. Shares of Gilead Sciences Inc. rose by 0.79% in the last five trading days and 4.1% for the last 4 weeks. In a related news, Milligan John F, director officer (President and CEO) of Gilead Sciences Inc, unloaded 112,000 shares at an average price of $84.62 on July 5, 2016. The total amount of the transaction was worth $9,477,440, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Gilead Sciences (NASDAQ:GILD): stock turned positive on Monday. Though the stock opened at $86.94, the bulls momentum made the stock top out at $87.34 level for the day. The stock recorded a low of $86.47 and closed the trading day at $86.93, in the green by 0.30%. The total traded volume for the day was 6,788,252. The stock had closed at $86.67 in the previous days trading.
Gilead Sciences, Inc. (Gilead), is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, oncology and inflammation, and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. Its Liver Diseases products include Harvoni, Sovaldi, Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.